Inovio Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
INO Inovio Pharmaceuticals Inc
GOLD Barrick Gold Corp
AMZN Amazon.com Inc
NFLX Netflix Inc
CDTX Cidara Therapeutics Inc
XBTAX BlackRock Long Term Municipal Advantage Trust
PBYA Probility Media Corp
RA Brookfield Real Assets Income Fund Inc.
PAA Plains All American Pipeline LP
$ESDOWD DOW JONES SPAIN STK US$ NDX
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Closing Price
$21.45
Day's Change
1.72 (8.72%)
Bid
--
Ask
--
B/A Size
--
Day's High
22.48
Day's Low
19.90
Volume
(Light)
Volume:
52,608,963

10-day average volume:
85,813,188
52,608,963

CLASS ACTION UPDATE for INO, ANAB and HAFC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

9:10 am ET May 12, 2020 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / May 12, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

INO Shareholders Click Here: https://www.zlk.com/pslra-1/inovio-pharmaceuticals-inc-loss-form?prid=6453&wire=1ANAB Shareholders Click Here: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=6453&wire=1HAFC Shareholders Click Here: https://www.zlk.com/pslra-1/hanmi-financial-corporation-loss-form?prid=6453&wire=1

* ADDITIONAL INFORMATION BELOW *

Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

INO Lawsuit on behalf of: investors who purchased February 14, 2020 - March 9, 2020Lead Plaintiff Deadline : May 12, 2020TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/inovio-pharmaceuticals-inc-loss-form?prid=6453&wire=1

According to a filed complaint, throughout the class period, defendants made misleading statements about the company's development of a purported vaccine for the novel coronavirus, artificially inflating the company's share price and resulting in significant investor losses.

AnaptysBio, Inc. (NASDAQ:ANAB)

ANAB Lawsuit on behalf of: investors who purchased October 10, 2017 - November 7, 2019Lead Plaintiff Deadline : May 26, 2020TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=6453&wire=1

According to the filed complaint, during the class period, AnaptysBio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.

Hanmi Financial Corporation (NASDAQ:HAFC)

HAFC Lawsuit on behalf of: investors who purchased August 12, 2019 - January 28, 2020Lead Plaintiff Deadline : May 26, 2020TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/hanmi-financial-corporation-loss-form?prid=6453&wire=1

According to the filed complaint, during the class period, Hanmi Financial Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the $40.7 million troubled loan that the Company disclosed on conference calls would necessitate further and future specific provisions for the Company - in the millions; (2) the same $40.7 million troubled loan would necessitate the Company to appraise and take personal property securing a portion of the amount of the loan; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.55 Broadway, 10th FloorNew York, NY 10006jlevi@levikorsinsky.comTel: (212) 363-7500Fax: (212) 363-7171www.zlk.com

SOURCE: Levi & Korsinsky, LLP

View source version on accesswire.com: https://www.accesswire.com/589496/CLASS-ACTION-UPDATE-for-INO-ANAB-and-HAFC-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.